Proper name: Imatinib mesylate Type: Anticancer Drug Developer: Novartis AG Location: Basel, Switzerland Website: www.novartis.com Indication(s): For the treatment of Ph+ chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs), acute lymphoblastoid leukemia (ALL), chronic eosinophilic leukemia, myelodysplastic disease, aggressive systemic mastocytosis and dermatofibrosarcoma Approval Date: May 2001 2007 Revenue: $3.050 billion Percentage of Novartis' Total Revenue: 8

Proper name: Adalimumab Type: Anti-inflammatory agent Developer: Abbott Laboratories Location: Abbott Park, Illinois Web address: www.abbott.com Indication(s): For the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, polyarticular juvenile idiopathic arthritis and Crohn's disease Approval Date: December 2002 2007 Revenue: $3.064 billion Percentage of Abbott's Total Revenue: 11.82 percent Approvals and Indications Approved for five

Proper name: Insulin glargine (rDNA origin) Type: Long-acting insulin diabetes therapeutic Developer: Sanofi-Aventis Location: Paris, France Web address: www.sanofi-aventis.com Indication(s): Adults with Type II diabetes or adults and children (6 years and older) with Type I diabetes who require long-acting insulin for the control of high blood sugar Approval Date: April 2000 2007 Revenue: $3.16 billion Percentage of Sanofi-Aventis's Total Revenue: 7.25 percent About Lantus It is very

Proper name: Infliximab Type: Anti-inflammatory Drug Developer: Centocor Inc. Location: Malvern, Pennsylvania Website: www.centocor.com Indication(s): For the treatment of moderately to severely active Crohn's disease, reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in patients with fistulizing Crohn's disease; for the treatment of active ankylosing spondylitis; for reducing signs and symptoms of active arthritis in patients with

Proper name: Darbepoetin alpha Type: Antianemic Drug Developer: Amgen Inc. Location: Thousand Oaks, California Website: www.amgen.com Indication(s): To treat anemia associated with chronic renal failure and to treat chemotherapy-induced anemia in patients with nonmyeloid malignancies Approval Date: September 2001 2007 Revenue: $3.614 billion Percentage of Amgen's Total Revenue: 24.47 percent Anemia Indication Chronic renal failure, also called kidney failure, is described as "a

Proper name: Bevacizumab Type: Anticancer Developer: Genentech Inc. Location: South San Francisco, California Web address: www.gene.com Indication(s): For the first and second-line treatment of metastatic colorectal cancer in combination with intravenous 5-fluorouracil (5-FU)-based chemotherapy. In combination with carboplatin and paclitaxel, for the first-line treatment of inoperable advanced, recurrent or metastatic non-squamous, non-small-cell lung cancer. Also, combined with paclitaxel

Proper name: Trastuzumab Type: Anticancer Drug Developer: Genentech Inc. Location: South San Francisco, California Website: www.gene.com Indication(s): To treat early and metastatic breast cancer in HER2-positive women, including combinations with chemotherapy, aromatase inhibitors and hormonal therapy. Approval Date: September 1998 Total 2007 Revenue (Reported by Roche Group): $4.809 billion 2007 Revenue Reported by Genentech: $1.287 billion Percentage of Roche Group's Total Revenue

Proper name: Etanercept Type: Anti-inflammatory Drug Developer: Amgen Inc. Location: Thousand Oaks, California Website: www.amgen.com Indication(s): To reduce the signs and symptoms of moderate to severe rheumatoid arthritis, moderate to severe polyarticular-course juvenile rheumatoid arthritis (JRA), psoriatic arthritis, ankylosing spondylitis (AS) and moderate to severe plaque psoriasis. Approval Date: November 1998 2007 Revenue: $5.275 billion Percentage of Amgen's Total Revenue: 35

Proper name: Rituximab Type: Anticancer, anti-inflammatory Drug Developer: Genentech Inc. Location: South San Francisco, California Website: www.gene.com Indication(s): For the treatment of relapsed or refractory low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL), slow-growing NHL, aggressive NHL in combination with the chemotherapy drugs cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP), to diffuse large B-cell lymphoma in combination with CHOP or other chemotherapy

Drug name (maker) Indication Revenue for 2007 1 Rituxan (Genentech) Non-Hodgkin's lymphoma, rheumatoid arthritis $5,467M 2 Enbrel (Amgen) Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis $5,275M 3 Herceptin (Genentech) Breast cancer $4,809M 4 Avastin (Genentech) Colorectal cancer, non-small-cell lung cancer $4,070M 5 Aranesp (Amgen) Anemia $3,614M 6 Remicade (J&J) Crohn's disease, ankylosing spondylitis, arthritis, ulcerative colitis

Bet on Red Red biotechnology, the application of biological processes in medical applications, has been growing in size, value and resourcefulness for more than a decade, and its most essential achievement may be its proclivity to deflect, rather than collide with, damaging adversity that can send entire markets into ruin or prolonged disrepair. That characteristic is grounded in the well-regarded innovation that has developed a reputation strong enough to attract financial support and convert

Company Product / Description / Indication Status (Date) Anadys Pharmaceuticals Inc. and Novartis AG ANA975; Oral prodrug of isatoribine, a Toll-like receptor-7 agonist for hepatitis C Suspended dosing in Phase Ib trial pending additional analysis of recently seen toxicology studies in animals (6/26/06) AVI BioPharma Inc. AVI-4065; Neugene antisense compound for hepatitis C First phase of trial demonstrated positive safety and pharmacokinetic data in 30 healthy volunteers (1/10/06

All figures are in U.S. dollars unless otherwise indicated. Abbott Laboratories (*health care company) YE 2006 YE 2005 Revenue $22.476B $22.338B Net income $1.717B $3.372B Earnings per share $1.12/share $2.16/share Average shares outstanding 1.537B 1.564B Market capitalization 83.48B (3/07)** 69.24B (3/06)* Amgen Inc. (*biotechnology company) YE 2006 YE 2005 Revenue $14.268B $12.430B Net income $2.950B $3.674B Earnings per share $2.51/share $2.97/share Average

Drug name (maker) 2006 2005 2004 2003 1 Enbrel (Amgen) $4,379M $3,673M $1,900M (Amgen only) $1,300M (Amgen only) 2 Aranesp (Amgen) $4,121M $3,273M $2,500M $1,600M 3 Rituxan (Genentech) $3,881M $1,831M $1,574M $1,489M 4 Procrit/Eprex (Ortho Biotech) $3,180M $3,324M $3,589M $3,984M 5 Herceptin (Genentech) $3,150M $2,416M $1,591M $2,064M 6 Remicade (J&J) $3,014M $2,535M $2,145M $1,729M 7 Neulasta (Amgen) $2,710M $2,288M $1,700M $1,300M 8 Gleevec

Thermo Fisher Scientific Inc. $3,792M Applied Biosystems Inc. $1,911M Sigma-Aldrich Corp. $1,798M bioMerieux SA $1,372M Invitrogen Corp. $1,263M Millipore Corp. $1,255M PPD Inc. (Pharmaceutical Product Development Inc.) $1,248M Idexx Laboratories Inc. $739M Qiagen NV $466M Affymetrix Inc. $355M Gen-Probe Inc. $355M Bruker Biosciences Corp. $436M Takara Bio Inc. $141M SOURCE: BioScan: The Worldwide Biotech Industry Reporting Service

Amgen Inc. $14,268M Genentech Inc. $9,284M Genzyme Corp. $3,187M Gilead Sciences Inc. $3,026M Merck Serono SA $2,805M Biogen Idec Inc. $2,683M Cephalon Inc. $1,764M MedImmune Inc. $1,277M Celgene Corp. $899M ImClone Systems Inc. $678M PDL BioPharma Inc. $415M Affymetrix Inc. $355M Albany Molecular Research Inc. $180M QLT Inc. $175M Alkermes Inc. $166M Takara Bio Inc. $141M Aeolus Pharmaceuticals Inc. $92M Acambis plc $61M AEterna Zentaris Inc. $41M SOURCE

Amgen Inc. 20,000 Actelion Ltd. 1,250 Genentech Inc. 10,500 Affymetrix Inc. 1,130 Genzyme Corp. 9,000 PDL BioPharma Inc. 1,100 CSL Ltd. 6,500 Albany Molecular Research Inc. 1,015 Merck Serono SA 4,775 ImClone Systems Inc. 990 Biogen Idec Inc. 3,750 Takara Bio Inc. 940 Cephalon Inc. 2,895 Promega Corp. 850 Gilead Sciences Inc. 2,515 Human Genome Sciences Inc. 770 Sepracor Inc. 2,470 Alkermes Inc. 760 MedImmune Inc. 2,360 Myriad Genetics Inc. 720 Ortho

(in millions of U.S. dollars)

Money Raised by Biotech in 2006: January–December (in millions of U.S. dollars) Public offerings Private biotechs Public/other Total Jan. 542.2 476.3 386.5 1,405.0 Feb. 486.8 306.3 532.5 1,325.6 March 922.3 380.8 1,214.1 2,517.2 April 574.3 377.1 1,945.1 2,896.4 May 267.8 511.6 424.6 1,203.9 June 317.4 398.1 228.6 944.1 July 32.2 276.1 459.3 767.6 Aug. 141.8 578.0 124.1 843.9 Sept. 325.6 477.7 183.8 987.1 Oct. 360.0 529.7 759.1 1,648.8